Tradestie Institutional Equity Comparison Engine
AXNX vs ABT โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
ABT Overall Edge
ABT Captures Institutional Edge (3โ1 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Abbott Laboratories (ABT) driven by superior Valuation, Growth & Margin, Options & Structure while AXNX counters with relative strength in Momentum & Technical. Fundamentally, AXNX trades at N/M Forward P/E with N/A operating margin (N/A YoY revenue) versus ABT at 17.4x Forward P/E and 15.7% operating margin (+14.5% YoY). In options structure, AXNX sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against ABT sits in CONSOLIDATION (11th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
ABT
AXNX N/M vs ABT 17.4x Fwd P/E
Growth & Margin Winner
ABT
Op Margin N/A vs 15.7% ยท YoY N/A vs +14.5%
Momentum & Technical Winner
AXNX
1Y +16.9% vs -18.4% ยท 52W Pos 50% vs 42%
Options & Structure Winner
ABT
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (11th %ile IV)
AXNX
US Equity
AXNX
Institutional Equity
$0.83
-8.28% 1D
Market Cap
N/A
1M Return
-26.54%
1Y Return
+16.92%
Forward P/E
N/M
Unified AI Score
52.1 / 100
HOLD
Tech 50.0
Fund 50.0
Flow 50.0
Mom 50.0
ABT
NYSE
Abbott Laboratories
Pharmaceutical Preparations
$103.00
-0.84% 1D
Market Cap
$179.9B
1M Return
+0.48%
1Y Return
-18.35%
Forward P/E
17.4x
Unified AI Score
42.6 / 100
HOLD
Tech 25.0
Fund 47.0
Flow 69.0
Mom 50.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
AXNX +16.92%
ABT -18.35%
Spread: +16.54 pp (AXNX Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
AXNX TTM Op. Margin: N/A
ABT TTM Op. Margin: 15.7%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on AXNX vs ABT. Trailing 12-month operating profitability (AXNX N/A vs ABT 15.7%) and valuation multiples (AXNX N/M vs ABT 17.4x Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | AXNX | ABT | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | N/A | $179.9B | Larger Scale | ABT |
| Trailing P/E Ratio Valuation | N/M | 38.8x | Lower Multiple | ABT |
| Forward P/E Ratio Valuation | N/M | 17.4x | Lower Multiple | ABT |
| Revenue Growth (YoY) Growth | N/A | +14.5% | Higher Growth | ABT |
| Operating Margin (TTM) Profitability | N/A | 15.7% | Higher Margin | ABT |
| Net Profit Margin Profitability | N/A | 9.8% | Higher Margin | ABT |
| Return on Equity (ROE) Capital Efficiency | N/A | 9.1% | Higher ROE | ABT |
| 52-Week Range Position Momentum | 50% ($0โ$1) | 42% ($82โ$131) | Stronger Trend | AXNX |
| Beta / 30D Volatility Risk Regime | N/A | 0.04ฮฒ ยท 32% Vol | Lower Realized Risk | ABT |
| Unified Institutional Score Composite Signal | 52.1 / 100 (HOLD) | 42.6 / 100 (HOLD) | Higher Composite | AXNX |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full AXNX vs ABT Buy Guide
AXNX
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
ABT
CONSOLIDATION
64d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
11th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither AXNX nor ABT registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.